Samsung Life Science Fund invests in Swiss bio company... "Possesses next-generation ADC technology"

Strategic Investment in Araris Biotech
Support for Additional Development of ADC Candidate Substances
Possesses Linker Technology That Does Not Require Antibody Redesign

Samsung is investing in Araris Biotech AG, a Swiss biotech company developing antibody-drug conjugate (ADC) technology.

Araris Biotech logo.

Samsung C&T Corporation and Samsung Biologics announced on the 12th that they have invested in Araris Biotech through the "Samsung Life Science Fund." In July 2021, Samsung established a fund worth 150 billion KRW aimed at discovering new business opportunities in the bio sector. Prior to Araris's Series A investment round, Samsung participated as the sole strategic investor. The investment will be used to support the further development of Araris's ADC candidate substances.

Araris possesses linker technology that plays a crucial role in ADC drug development. Their linker platform can attach drugs to off-the-shelf antibodies without the need to redesign the antibodies. According to Samsung, this creates highly homogeneous, stable, and therapeutically effective ADCs. Additionally, it is known to have high potential to reduce the time and cost of drug development and to solve existing issues such as scalability and stability.

Through this investment, Samsung plans to collaborate with Araris in the production and development of ADC therapeutics. At the same time, Samsung aims to strengthen its ADC capabilities and further expand its related portfolio.

John Lim, CEO of Samsung Biologics, stated, "Araris Biotech has the potential to develop best-in-class ADC therapeutics, and we will explore collaboration opportunities in new drug manufacturing and development in the future."

This content was produced with the assistance of AI translation services.